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Daniel Polsky1,4*, Machaon Bonafede2 and Jose A Suaya3Abstract
Background: Adults with certain comorbid conditions have a higher risk of pneumonia than the overall
population. If treatment of pneumonia is more costly in certain predictable situations, this would affect the value
proposition of populations for pneumonia prevention. We estimate the economic impact of community-acquired
pneumonia (CAP) for adults with asthma, diabetes, chronic obstructive pulmonary disease (COPD) and congestive
heart failure (CHF) in a large U.S. commercially-insured working age population.
Methods: Data sources consisted of 2003 through 2007 Thomson Reuters MarketScan Commercial Claims and
Encounters and Thomson Reuters Health Productivity and Management (HPM) databases. Pneumonia episodes and
selected comorbidities were identified by ICD-9-CM diagnosis codes. By propensity score matching, controls were
identified for pneumonia patients. Excess direct medical costs and excess productivity cost were estimated by
generalized linear models (GLM).
Results: We identified 402,831 patients with CAP between 2003 through 2007, with 25,560, 32,677, 16,343, and
5,062 episodes occurring in patients with asthma, diabetes, COPD and CHF, respectively. Mean excess costs (and
standard error, SE) of CAP were $14,429 (SE=44) overall. Mean excess costs by comorbidity subgroup were lowest
for asthma ($13,307 (SE=123)), followed by diabetes ($21,395 (SE=171)) and COPD ($23,493 (SE=197)); mean excess
costs were highest for patients with CHF ($34,436 (SE=549)). On average, indirect costs comprised 21% of total
excess costs, ranging from 8% for CHF patients to 27% for COPD patients.
Conclusions: Compared to patients without asthma, diabetes, COPD, or CHF, the excess cost of CAP is nearly twice
as high for patients with diabetes and COPD and nearly three times as high for patients with CHF. Indirect costs
made up a significant but varying portion of excess CAP costs. Returns on prevention of pneumonia would
therefore be higher in adults with these comorbidities.
Keywords: Community-acquired pneumonia (CAP), Medical cost, Productivity cost, Economic evaluation, Asthma,
Diabetes, Chronic Obstructive Pulmonary Disease (COPD), Congestive Heart Failure (CHF)Background
Community-acquired pneumonia (CAP) ranks among
the top causes of death and hospitalization and it is a
major driver of health care utilization and cost. Annu-
ally, there are 2 to 3 million CAP cases in the US result-
ing in half a million hospitalizations, 10 million
physician visits, and 45,000 deaths [1]. A recent study of* Correspondence: Polsky@mail.med.upenn.edu
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reproduction in any medium, provided the orUS non-elderly adults estimated that CAP was asso-
ciated with annual excess medical costs of $8.5 billion
and a productivity loss of $2.1 billion [2]. While it is
understood that pneumonia risks are elevated for certain
groups including several common comorbidities such as
asthma and COPD [3-7], the cost burden of pneumonia
has not been explored within comorbidity subgroups.
We estimate the total excess cost burden of CAP as the
sum of medical costs and productivity losses (work ab-
sence and short-term disability) in a large cohort of com-
mercially insured working-age adults throughout the
United States for the most common comorbiditiestd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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COPD, and CHF [2,8]. In addition to being common,
these comorbidities have been singled out as potential
risk factors for complications and/or mortality during or
following a pneumonia episode [4,9-12]. As a result, costs
of pneumonia may be higher when these comorbidities
are present. In this paper we explore this possibility from
the perspective of employers who insure adult popula-
tions and face the burden of medical costs and costs of
absenteeism and disability.
Methods
Data and sample selection
This project utilized two Thomson Reuters’ research
proprietary databases. For estimations of medical cost,
the study is based on medical and outpatient prescrip-
tion drug claims of employees and dependents in the
MarketScan Commercial Claims (Commercial) and
Encounters database, which included 34 million cov-
ered lives in 2008. For estimations of productivity cost,
the study used workplace absenteeism and short-term
disability data from the Health Productivity and Man-
agement (HPM) database. The HPM database is con-
structed from administrative payroll system data that
includes missed work, short-term disability, and work-
er’s compensation from some of the same employers
that have provided health care claims. HPM data has
been widely used in academic publications [2,13-16].
HPM data is available for 1.4 million of the employees
included in the Commercial database. Both the Com-
mercial and HPM databases contain de-identified data
that are in compliance with the Health Insurance Port-
ability and Accountability Act (HIPAA) regulations;
thus this analysis was exempt from Institutional Re-
view Board approval. We studied adults aged 18–64
years enrolled in health plans between July 31, 2002
and December 31, 2007 with at least 6-months of con-
tinuous medical and prescription coverage.
Pneumonia episodes were identified by ICD-9-CM
diagnosis codes (480.xx-486.xx) in (1) a principal or
non-principal diagnosis on an outpatient claim or (2) a
principal diagnosis on an inpatient claim. An index date
for pneumonia was defined as the date of its first diag-
nosis without any similar diagnosis (i.e., pneumonia) in
the prior six-months.
In order to obtain comparable controls, a control
group was created from a pool of controls using a near-
est neighbor propensity score 1:3 case:control match
without replacement. The pool of potential controls was
constructed from all individuals without pneumonia. To
allow pre-index group comparisons and identification of
selected comorbidities, control patients had a randomly
assigned index date and were required to also have 6
months of continuous medical and prescription coveragepreceding the index date. The propensity score of the
presence of a pneumonia diagnosis was based on a logis-
tic regression using the following covariates: index year,
quarter, age, gender, geographic region, plan capitation
status, industry, length of follow-up, baseline Deyo
Charlson Comorbidity Index, and baseline comorbid
conditions, including asthma, diabetes, cancer, cardiovas-
cular disease, CHF, COPD, and HIV. We used this same
technique to obtain controls for the subset of patients
with work absence and short-term disability data.
There was no minimum enrollment time requirement
following the index dates for cases and controls. The
maximum follow-up time was 12 months from the index
date, depending on enrollees' data availability.
As the focus of this study was community-acquired
pneumonia (CAP), we excluded from the cost analysis
any health-care associated or hospital-acquired pneumo-
nia, which was defined as principal diagnosis on an in-
patient claim that had evidence of an acute-inpatient or
long-term care stay in the previous 30 days.Cost variables
The outcome variables include three components of
medical costs: inpatient, outpatient, and pharmacy; and
two components of productivity costs: absenteeism costs
and short-term disability costs.
Medical costs were defined as total gross payments to
a provider, including deductibles, copayments, and co-
ordination of benefits. Costs were tabulated separately
for inpatient medical, outpatient medical, and outpatient
pharmacy. The costs of emergency room visits that led
to an inpatient visit were classified as inpatient medical;
all others were classified as outpatient medical. Pharma-
ceutical costs equaled the actual reimbursement to the
pharmacy, including the drug’s administrative dispensing
fee, ingredient cost, patient portion of costs, and sales
tax. A payment proxy based on procedure code and re-
gion of care by the data provider was estimated for
expenditures for services provided under capitation
arrangements. All medical costs were adjusted to 2008
dollars using the Medical Care-Specific Consumer Price
Index.
To estimate the cost of absenteeism, the number of
employer-recorded days of absence from work was
multiplied by a wage constant of $41/hour. This wage is
based on a previous benchmarking study of health and
productivity-related costs from a sample of 32 compan-
ies across the US [17] and adjusted to 2008 US $ using
the US National Wage Index [18]. To estimate costs of
short-term disability, the number of short-term disability
days was multiplied by a $28.70/hr wage constant as a
result of the observation that average wage replacement
tends to be 70% of wages while on disability. This 70%
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[19,20].
Analysis
Our strategy to estimate excess costs was to use a multi-
variate model with cases and controls with excess costs
defined as the adjusted difference in costs between cases
and controls. By including a control variable for number
of months of data availability following the index date,
we annualize costs through a post-estimation prediction
under the assumption that all subjects are followed for
12 months.
Based on a comprehensive comparison of estimation
methods in earlier analyses on costs of pneumonia [2],
we estimated costs using the generalized linear model
(GLM) with a gamma family and a log link. Due to the
distinct cost distribution for each cost outcome, separate
models were estimated for total inpatient cost, ambula-
tory care excluding pharmacy cost, and pharmacy cost.
Predicted costs were then summed in order to assess
total costs. Similarly, separate models were estimated to
assess absenteeism and short-term disability. For in-
patient costs, absenteeism, and short-term disability,
two-part models were used. The control variables for all
multivariate models included demographic, clinical and
cost covariates. Demographic covariates included: age,
gender, insurance type, US Bureau of Census region of
residence, and population density status (urban vs.
rural), employee class (union vs. non-union), employ-
ment status, and employee relationship. Clinical covari-
ates included: Deyo CCI score in pre-period, COPD,
congestive heart failure, cancer, cardiovascular disease,
other musculoskeletal surgery, diabetes, asthma, pre-
period medication use (specifically, antibiotics, long-acting
beta agonists, short-acting beta agonists, or systemic ster-
oids), an indicator of whether there was a hospitalization
in the 1 month prior to index date, and time observed for
follow-up. Cost covariates (adjusted to 2008 US dollars)
included: total inpatient costs in pre-period, total out-
patient costs in pre-period, and total pharmacy costs in
pre-period.
Separate models were estimated for all subjects and
for each of the selected comorbidity subgroups (asthma,
diabetes, COPD, CHF). We note these comorbidity sub-
groups are not mutually exclusive. A separate subgroup
was defined by the absence of all four of these comor-
bidities. Code lists are available from the authors upon
request.
Results
We identified 402,831 patients with CAP from Market-
Scan Commercial Claims (Commercial) and Encounters
database. The overall demographic characteristics and
pre-index period clinical characteristics are shown inTable 1. The mean age of CAP patients was 47 years and
45.6% were male. The most prevalent comorbid condi-
tions were cardiovascular disease (22.2%), diabetes
(8.1%), asthma (6.3%), cancer (6.0%), and COPD (4.1%).
Mean length of follow-up was 318 days. Pre-period out-
patient costs were nearly $3,000. This high baseline out-
patient cost is driven by the high volume of cases with
comorbidities. For example, pre-period outpatient costs
were over $6,000 for cases with comorbidities of COPD,
diabetes, and CHF.
Demographic characteristics were similar between
CAP patients and their 1,425,045 matched controls as
the standardized differences were typically in the 1-3%
range. The highest standardized differences were COPD
at 7.29, comprehensive insurance at 7.39, and pre-period
outpatient costs with standardized differences above 10;
multivariate models were used to control for these
remaining imbalances.
Annualized adjusted excess total medical costs of a
case of CAP were estimated at $11,395 (SE=$42) across
all patients, as determined by the difference between
estimated costs for patients with CAP ($17,640 (SD=
$26,706)) and the control patients ($6,245 (SD=
$16,189)). These estimates come from costs defined in
2008 dollars as total gross payments to a provider, in-
cluding deductibles, copayments, and coordination of
benefits.
Excess medical costs of CAP among patients with
COPD, diabetes, and CHF are higher than the average
excess medical costs of CAP. Pneumonia is most costly
among CHF patients at $31,593 (SE=$531). Excess costs
are also substantially higher for patients with COPD
($17,039 (SE=$186)) and diabetes ($16,351 (SE=$165)).
Among the comorbidities of interest, CAP with asthma
had the lowest total excess medical costs at $10,158
(SE=$109). All of these costs were higher than the excess
costs of CAP for patients without CHF, COPD, diabetes,
or asthma ($9,866 (SE=$43)).
The detail of medical costs by each cost component
sheds light on the drivers of higher excess medical costs
among the comorbidity subgroups. As shown in Table 2,
excess inpatient costs were highest among CHF patients
($18,339 (SE=$163)) and lowest among asthma patients
($4,908 (SE=38). Excess outpatient costs were highest
among CHF patients ($11,953 (SE=387)) and lowest
among asthma patients ($4,210 (SE=62)). Excess out-
patient pharmacy costs appeared more similar across the
comorbidity groups, ranging from $1,040 (SE=19) for
asthma patients to $1,565 (SE=29) for COPD patients.
As shown in Table 3, productivity costs are $3,034
(SE=$55) higher for patients with pneumonia than the
controls; approximately two-thirds of this difference is
driven by short-term disability costs while the remainder
comes from absenteeism costs. Among the comorbidity
Table 1 Baseline characteristics of patients aged 18-64 years with community acquired pneumonia (CAP) and
non-pneumonia controls
Pneumonia Cases Non-Pneumonia Controls Standardized Difference (%)
Sample Size 402,831 1,203,823 Not applicable
Sociodemographics characteristics of patients
Male 45.6% 45.9% 0.58
Age in years, mean (sd) 46.8 (12.2) 46.5 (12.3) 2.37
Age group (yrs.) 0.00
18-34 17.6% 17.6% 0.02
35-44 20.8% 20.9% 0.02
45-54 28.4% 28.8% 0.87
55-64 33.1% 32.7% 0.87
Comorbid conditions in patients 0.00
Charlson-Deyo index, mean (sd) 0.44 (1.07) 0.45 (1.02) 0.74
Selected for excess cost analyses
Asthma 6.3% 6.0% 1.31
Diabetes 8.1% 8.6% 1.65
COPD 4.1% 2.7% 7.23
Congestive heart failure 1.3% 1.1% 1.91
Others
Cardiovascular disease 22.2% 23.0% 1.93
Cancer 6.0% 6.2% 0.98
HIV/AIDS 0.3% 0.3% 0.39
Hepatitis B 0.0% 0.0% 0.12
Hepatitis C 0.4% 0.2% 2.30
Orthopedic Surgery 0.1% 0.2% 1.27
Other Musculoskeletal Surgery 2.2% 2.3% 0.98
Pregnancy 0.8% 1.0% 1.40
Patient's follow-up in days, mean (sd) 318.2 (97.6) 318.4 (100.1) 0.20
Insurance plan type
Preferred Provider Organization (PPO) 55.0% 56.3% 2.50
Health Maintenance Organization (HMO) 20.2% 19.9% 0.80
Point of Service (POS) 10.4% 10.4% 0.16
Comprehensive 8.7% 6.8% 7.27
Other 5.6% 6.6% 4.07
Plan Type
Capitated 21.7% 21.7% 0.13
Geographic region
Northeast 10.6% 10.7% 0.43
North Central 27.0% 26.6% 0.90
South 41.8% 42.4% 1.13
West 20.2% 19.9% 0.68
Unknown 0.5% 0.4% 0.30
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Table 1 Baseline characteristics of patients aged 18-64 years with community acquired pneumonia (CAP) and
non-pneumonia controls (Continued)
Urban/Rural residence
Urban 80.6% 82.2% 4.33
Rural 19.0% 17.4% 4.29
Unknown 0.4% 0.4% 0.46
Industry type
Manufacturing, Durable Goods 20.8% 20.7% 0.29
Transportation, Communications, Utilities 10.5% 10.6% 0.56
Services 6.3% 6.3% 0.23
Manufacturing, Nondurable Goods 5.4% 5.5% 0.54
Finance, Insurance, Real Estate 5.3% 4.9% 1.88
Retail Trade 4.5% 4.9% 2.05
Oil & Gas Extraction, Mining 0.8% 0.8% 0.36
Unknown 46.4% 46.2% 0.45
Dependent status
Employee 63.3% 62.3% 2.09
Dependent 36.7% 37.7% 2.09
Pre-period Expenditures
Total inpatient costs $1,005 ($10,752) $1,078 ($9,746) 0.71
Total outpatient costs $2,927 ($12,033) $1,896 ($7,291) 10.36
Total outpatient pharmacy costs $1,055 ($2,318) $686 ($1,704) 18.14
Abbreviations: sd, standard deviation.
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($6,454 (SE=$329)) and diabetes ($5,044 (SE=$263)) and
lowest for CHF ($2,842 (SE=$752).
Table 4 contains the adjusted overall excess cost of
CAP, which are also depicted in Figure 1. CHF patients
had the highest total burden of CAP, with costs nearly
three times the average excess costs of CAP. CAP for
patients with COPD and diabetes costs 86% and 70%
more than for a typical patient. The excess cost of CAP
for patients with asthma appeared similar to the average
excess cost of CAP. On average, the excess cost of CAP
was 79% excess direct costs and 21% excess indirect
costs. The relationship between excess direct and indir-
ect costs was similar for patients with asthma, diabetes
and COPD where indirect costs accounted for 24-27% of
total excess costs. Among patients with CHF, total ex-
cess costs were predominantly direct costs (92%) com-
pared to indirect costs (8%).
Discussion
The objective of this study was to estimate, for selected
comorbidities, the excess health care costs and employer
productivity costs of working age adults with CAP. The
excess costs per case of CAP in the working-age adult
population was $14,429 overall, but could be nearly 3
times as high among patients with CHF and around75% higher among patients with COPD and diabetes.
When considering the reduced cost burden from pre-
vention of CAP, it is not sufficient to consider the risks
of acquiring pneumonia, the fact that the cost per case
can vary among different risk groups must be taken
into account. As a result, we have provided key esti-
mates of the burden of disease among key comorbidity
risk groups.
The cost per CAP patient is highest for patients with
CHF ($34,436) and is substantially higher than the cost
of CAP for patients with other conditions such as COPD
($23,439), diabetes ($21,395) and asthma ($13,307), and
particularly those without any of these selected comor-
bidities ($12,601). The higher costs, particularly for CHF
and even for COPD may be explained by the clinical evi-
dence which suggests that the pre-existing condition has
a detrimental effect on pneumonia prognosis [10,21],
but there is also evidence that pneumonia contributes to
an exacerbation of the original condition [9,22]. These
estimates can be used to better understand the cost of
preventing a case of CAP, which would clearly be higher
among patients with CHF than if prevention was driven
only by the risks of being diagnosed with pneumonia.
With no other comorbidity-specific estimates of pneu-
monia costs, these results cannot be directly compared
to other studies in the literature, but the overall
Table 2 Annualized adjusted excess medical cost of community acquired pneumonia by selected comorbidity group
Attribute Pneumonia
Group
All Patients No key
comorbidity
Comorbid group
Asthma Diabetes COPD CHF
Sample size PNA Cases 402,831 333,485 25,560 32,677 16,343 5,062
Controls 1,425,045 1,155,049 92,524 131,544 50,785 20,814
Cost component
Inpatient PNA Cases Mean $5,373 $4,235 $6,884 $12,111 $12,452 $27,534
(SD) ($6,022) ($4,689) ($6,042) ($9,363) ($8,390) ($11,604)
Controls Mean $1,472 $1,093 $1,976 $3,706 $3,676 $9,195
(SD) ($2,548) ($1,833) ($2,718) ($4,706) ($3,770) ($5,925)
Excess cost
of PNA
Mean $3,900 $3,143 $4,908 $8,404 $8,777 $18,339
(SE) ($9) ($8) ($38) ($52) ($66) ($163)
As % of total
medical cost
34% 32% 48% 51% 52% 58%
Outpatient PNA Cases Mean $9,236 $8,089 $9,304 $14,130 $13,634 $24,713
(SD) ($18,160) ($17,234) ($9,887) ($20,046) ($14,641) ($27,510)
Controls Mean $3,441 $2,843 $5,094 $7,278 $6,937 $12,760
(SD) ($6,765) ($6,057) ($5,413) ($10,325) ($7,449) ($14,204)
Excess cost
of PNA
Mean $5,796 $5,246 $4,210 $6,852 $6,698 $11,953
(SE) ($29) ($30) ($62) ($111) ($115) ($387)
As % of total
medical cost
51% 53% 41% 42% 39% 38%
Pharmacy PNA Cases Mean $3,031 $2,457 $3,582 $4,800 $4,695 $5,404
(SD) ($4,434) ($4,326) ($3,098) ($3,028) ($3,678) ($4,272)
Controls Mean $1,332 $979 $2,542 $3,706 $3,130 $4,103
(SD) ($1,949) ($1,725) ($2,198) ($2,338) ($2,452) ($3,244)
Excess cost
of PNA
Mean $1,698 $1,477 $1,040 $1,094 $1,565 $1,301
(SE) ($7) ($7) ($19) ($17) ($29) ($60)
As % of total
medical cost
15% 15% 10% 7% 9% 4%
Total medical PNA Cases Mean $17,640 $14,781 $19,770 $31,041 $30,781 $57,652
(SD) ($26,704) ($24,880) ($17,392) ($29,843) ($23,809) ($37,756)
Controls Mean $6,245 $4,915 $9,612 $14,690 $13,742 26,059
(SD) ($10,549) ($9,179) ($9,373) ($15,955) ($12,216) ($20,440)
Excess cost of PNA Mean 11,395 $9,866 $10,158 $16,351 $17,039 31,593
(SE) ($42) ($43) ($109) ($165) ($186) ($531)
Abbreviations: PNA, pneumonia; COPD, chronic obstructive pulmonary disease; CHF, congestive heart failure; SD, standard deviation; SE, standard error.
Note: comorbid groups are not mutually exclusive. Cost estimates are from generalized linear regressions.
All excess cost estimates are significant at p<0.01.
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our work suggests that productivity costs are about 20%
of total burden. The one previous analysis that included
productivity costs suggested that they represent 29% of
total cost [22]. Colice et al. performed a retrospective
claims-based analysis of CAP based on employer-
payments for medical care made by a single Fortune 100company in the time period from 1996 to 1998 [23].
This analysis found that the mean cost for an inpatient
episode of pneumonia was $8,942, while an ambulatory
CAP episode cost $466. The discrepancy in CAP costs
between the two studies is likely due, in large part, to
the escalation of health care expenditures over the previ-
ous decade and the cost time horizon.




All Patients No key
comorbidity
Comorbid group
Asthma Diabetes COPD CHF
Absenteeism PNA Sample size 4,489 3,940 248 220 103 34
Mean $8,284 $8,158 $7,601 $10,502 $13,651 $9,043
(SD) ($2,571) ($2,362) ($3,464) ($4,627) ($7,919) ($7,962)
Controls Sample size 1 3,441 11,802 739 1,006 308 1 01
Mean $7,358 $7,233 $7,625 $8,384 $9,348 $9,181
(SD) ($2,284) ($2,095) ($3,475) ($3,694) ($5,423) ($8,084)
Excess cost of PNA Mean $926 $924 $(24) $2,118 $4,303 $(139)
(SE) ($38) ($38) ($220) ($312) ($780) ($1,366)
Short-term disability PNA Sample size 15,468 13,170 894 658 545 139
Mean $3,535 $2,997 $5,074 $5,124 $5,241 $7,170
(SD) ($7,258) ($5,456) ($8,505) ($6,287) ($2,697) ($5,866)
Controls Sample size 4 6,325 39,470 2,664 3,004 1,626 414
Mean $1,427 $1,187 $1,901 $2,198 $3,089 $4,190
(SD) ($2,929) ($2,161) ($3,186) ($2,696) ($1,590) ($3,428)
Excess cost of PNA Mean $2,108 $1,810 $3,173 $2,927 $2,151 $2,981
(SE) ($58) ($48) ($284) ($245) ($116) ($498)
Total productivity costs PNA Mean $11,819 $11,155 $12,675 $15,626 $18,891 $16,213
(SD) ($7,700) ($5,945) ($9,184) ($7,807) ($8,366) ($9,889)
Controls Mean $8,785 $8,420 9,526 $10,582 $12,437 $13,371
(SD) ($3,714) ($3,010) ($4,715) ($4,574) ($5,651) ($8,780)
Excess cost of PNA Mean $3,034 $2,734 $3,149 $5,044 $6,454 $2,842
(SE) ($55) ($45) ($272) ($263) ($329) ($752)
Abbreviations: PNA, pneumonia; COPD, chronic obstructive pulmonary disease; CHF, congestive heart failure; SD, standard deviation; SE, standard error.
Note: comorbid groups are not mutually exclusive. Cost estimates are from generalized linear regressions.
All excess cost estimates are significant at p<0.01 except for absenteeism in the asthma and CHF comorbid groups.
Table 4 Annualized adjusted total excess cost of community acquired pneumonia by selected comorbidity group
Type of excess cost All Patients No key
comorbidity
Comorbid group
Asthma Diabetes COPD CHF
Total medical Mean $11,395 $9,866 $10,158 $16,351 $17,039 $31,593
(SE) ($42) ($43) ($109) ($165) ($186) ($531)
(95% CI) ($11,312, $11,477) ($9,782, $9,951) ($9,945, $10,371) ($16,027, $16,674) ($16,674, $17,404) ($30,553, $32,634)
Total productivity
costs
Mean $3,034 $2,734 $3,149 $5,044 $6,454 $2,842
(SE) ($55) ($45) ($272) ($263) ($329) ($752)
(95% CI) ($2,927, $3,141) ($2,645, $2,823) ($2,616, $3,681) ($4,528, $5,561) ($5,810, $7,098) ($1,369, $4,316)
Total cost Mean $14,429 $12,601 $13,307 $21,395 $23,493 $34,436
(SE) ($44) ($44) ($123) ($171) ($197) ($549)
(95% CI) ($14,343, $14,514) ($12,514, $12,687) ($13,066, $13,548) ($21,061, $21,730) ($23,106, $23,880) ($33,360, $35,511)
Total cost relative to
patients without
selected comorbidities 1.15 1.00 1.06 1.70 1.86 2.73
Abbreviation: COPD, chronic obstructive pulmonary disease; CHF, congestive heart failure; SE, standard error; CI: confidence interval.
Note: comorbid groups are not mutually exclusive. Cost estimates are from generalized linear regressions.
All excess cost estimates are significant at p<0.01.
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Direct medical cost






Figure 1 Distribution of the annualized adjusted total excess cost of pneumonia by selected comorbidity group.
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reported no difference in median hospitalization costs
between patients with and without diabetes, CHF, or
COPD [24]. The analysis did not include outpatient
costs or a non-CAP comparison cohort. The study
reported a significant lack of literature describing the
impact of comorbidities on CAP-related costs. Bartolome
[25] and Niederman [26] evaluated age as a risk factor for
higher CAP-related costs. Reyes [24], Bauer [27], and
Kaplan [28] all reported higher pneumonia-related costs
associated with either more severe CAP cases or in the
presence of pneumonia-related complications, such as
pleural effusion or respiratory failure.
The analyses described herein have limitations.
While the MarketScan Research Databases represent a
wide variety of nationally-representative employed
patients and their dependents, it is not a random
sample. As a result, the study results may not be
generalizable to groups beyond the commercially
insured, such as Medicaid beneficiaries or unemployed
patients. Misclassification of pneumonia due to in-
accurate or absent diagnosis coding is possible when
analyzing claims data and basing the pneumonia diag-
nosis on ICD-9 codes alone and not on review of med-
ical records or X-ray results. For example, it is possible
that some mild cases were coded as “respiratory infec-
tion” and a few severe cases were coded as “sepsis”.
Likewise, the intention of this analysis was to describe
the burden of CAP separate from HAP; our ability to
differentiate CAP from HAP may be limited by infor-
mation available in an administrative claims database.
Including HAP cases in our cohort of CAP patients
could lead to an overestimation of the burden of CAP.However, to reduce the possibility of including HAP,
we excluded from the analysis any diagnosis of pneu-
monia in an inpatient claim that was based on a sec-
ondary diagnosis or even in a principal diagnosis if
there was evidence of an inpatient or long-term care
stay in the previous 30 days. Productivity costs are esti-
mated from the employer perspective and include only
missed work time, not work time completed at a
reduced productivity level. If illness affects labor force
participation or has an effect on long-term disability,
these productivity costs will not be captured. Finally,
our method of estimating “excess costs” depends on
the degree to which our matched control group is an
accurate representation of the counterfactual of what
the pneumonia patients would have experienced had
they not contracted pneumonia. This assumption is
not testable so our results must be interpreted in light
of this uncertainty.
Conclusion
In summary, we found that CAP is associated with sub-
stantial excess medical and productivity costs that can
vary substantially by comorbidity group. Excess costs per
case are highest for patients with a comorbidity of CHF
and also elevated for patients with diabetes and COPD.
Returns on prevention of pneumonia would therefore be
higher in adults with these comorbidities than in adults
without any of the selected comorbidities.
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